This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ImmunoGen's CEO Presents At Morgan Stanley Healthcare Conference - Transcript

Stocks in this article: IMGN

ImmunoGen, Inc. (IMGN)

ImmunoGen at Morgan Stanley Healthcare Conference

September 12, 2012 08:00 AM ET


Dan Junius, President and CEO


Marshall Urist - Morgan Stanley


Marshall Urist - Morgan Stanley

Good morning everyone and welcome to the precession of the third day of the Morgan Stanley 2012 Global Healthcare Conference. I am Marshall Urist one of the biotech analysts here at Morgan Stanley and before we get started just a couple of quick pieces of business. Number one, any of – all of our relevant research disclosures can be found in our website or on any piece of our research and second, it is absolutely supposed to be an open and interactive session so if you have questions please raise your hand and there are certainly microphones circulating. So, with that we are happy to be here this morning with Dan Junius, President and CEO of ImmunoGen. Dan, thanks for being with us this morning and maybe to start off take a few minutes to give sort of an overview of what you are focused on right now and what are the most kind of important things for people to think about in the next 12 months.

Dan Junius

Sure. Thanks Marshall and thank you for inviting us. Maybe just by the way of background in terms of the company, the technology, and our movement is some of the things that we are involved with. The company is built on a technology that uses the targeting ability of an antibody to find a target on a cancer cell and we’ve developed a technology that has both proprietary toxin that we use and a means of attaching that toxin to the antibody that is delivered for us a very effective targeted therapy for oncology.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs